Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   September 2015
 
A LA UNE
12/04/2015 - 7th edition of Private Inv€stments Day

This event organized by Lyonbiopole, will be held on Friday, December 4, 2015, at Sanofi Pasteur headquarters. The objective is to facilitate and develop contacts among SMEs and private investors. The full program is on our website.
Contact : Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com 

Learn more



ZOOM SUR
MaaT Pharma

The biotech MaaT Pharma, a Lyonbiopole's member, and implanted in AcCinov, specialised in the restauration of the Intestinal Microbiome successful fundraised € 1 million in July thanks to Seventure Partners. This new operation was carried out after MaaT Pharma signed a partnership with INRA, firsts significant scientific results for its autologous transplantation of gut microbiota flagship product for treating severe intestinal dybioses. This second million will allow the company to finance its development up to clinical phase. Maat Pharma has also been awarded at the French Worldwide Innovation Challenge for his project " Maat Ramp Up" which aims to treat the side effects of "gut microbiota " (dysbiosis) caused by the use of antibiotics treating infectious diseases.

Learn more



A LA UNE
10/07/2015 - The 9th edition of the Partnering Days

The 9th edition of the Partnering Days will take place on October, 7th 2015 at l'Hôtel de Région (Lyon-Confluence). The aim of the event, organised by Lyonbiopole, is to create R&D partnerships in the health sector between public and private actors in Rhône-Alpes. Registration are closed.
Contact : Claudia Chagneau, R&D Project Manager - claudia.chagneau@lyonbiopole.com 

Learn more


10/07/2015 - BlueSky Meeting, discover the projects of tomorrow !

For this 4th edition, 34 applications have been received and evaluated by an independent multidisciplinary committee. 20 of them have been selected - 10 in session 1 : innovative technology offers open to partnerships and 10 in session 2 : ideas for R&D projects in research partnerships. 20 flash presentations, of 5 minutes each, without question/answer, will be held in front of an audience of 250 participants. Registrations are closed.
Contact : Hugo Veysseyre, Clinical Innovation/Medical Technologies Project Manager - hugo.veysseyre@lyonbiopole.com

Learn more


10/07/2015 - Lyonbiopole is celebrating its 10th anniversary

On October, 7th, the cluster's team and its administrators will be pleased to share a friendly and festive time ! Registrations are closed.
Contact : Stéphanie Pelege, Communication Manager - stephanie.pelege@lyonbiopole.com

10/13-16/2015 - Lyonbiopole at Bio Japan


Lyonbiopole, with the support of the Rhône-Alpes Region and France Business, will participate at the BIO Japan Convention in Tokyo (Yokohama), Japan. This mission is organized around market seminars, visits to research institutes and BIO Japan.
Contact : Simon Gudin, SME's Development Project Manager - simon.gudin@lyonbiopole.com

Learn more


11/2-4/2015 - BIO Europe

Lyonbiopole alongside with its SME members, as Rhône-Alpes delegation will attend the Europe 2015 Convention BIO which be held in Munich, Germany. Each year, BIO Europe gather more than 3000 participants (1800 companies from 54 countries), with 18 000 meetings BtoB organised in 3 days. BIO-Europe is a unique occasion to highlight companies during the "Company Presentations". More than 160 companies present their activity each year.
Contact : Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more



AGENDA
Innovation Days
October 5th to 6th, 2015 - Paris, France
Partnering Days
October 7th, 2015 - Lyon, France
BIO JAPAN 2015
October 13th to 16th - Tokyo, Japan
BIO-Europe 2015
November 2nd to 4th, 2015 - Munich, Germany
BioFIT Fostering Innovation & Transfer
From December, 1st to 2nd, 2015 - Strasbourg, France
Private Inv€stments Day
December 4th,  2015 - Lyon, France
European Nanomedecine Meeting
December 7th to 9th, 2015 - Grenoble, France
 
A LA UNE
09/2015 – Upcoming H2020 « Health » calls for projects 

The European Commission has published pre-final version of the H2020 Health work programme 2016-2017; the calls should be open around mid-October (Participant Portal H2020). The aim is to enable stakeholders to already identify key issues and anticipate their future projects. Find the provisional "Health" program and other topics here. Lyonbiopole supports you to set-up European projects. 
Contact : Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

09/2015 – H2020 - Fast track to innovation Call open

The H2020 Fast Track to Innovation (FTI) programme is still open. It aims to give to innovative companies a final push before the access to market. The projects must focus on industrial development. Consortia should bring 3-5 organizations (mostly companies). All fields of technology are concerned. Last submission date in 2015: 12/1/2015.
Contact : Emilie Romeo, Europe Project Manager - emilie.romeo@lyonbiopole.com

Learn more


09/2015 – H2020 SME instrument – Last deadline 

H2020 program includes the SME instrument. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize; focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and / or diagnostic medical devices line and on 2 lines in the NMP and Biotech programs. The project can be presented by a single SME, and different phases depending on the maturity of the project. Las deadline for 2015: 11/25/2015. 
Contact : Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

09/2015 - 5th IMI call for projects open 
 

The Joint Technology Initiative on Innovative Medicines IMI2 launched July 9, 2015 its 5th call for projects. 6 topics are open. See details here. For the first stage of academic consortia compounds, SMEs, patient organizations, regulatory agencies are invited to respond to tenders. Closing date of the first stage: 10/13/2015. Preparation webinars were organized, find all the slides here.
Contact : Emilie Romeo, European Project Manager – emilie.romeo@lyonbiopole.com

09/2015 - Eurostars Programme

The next Eurostars call will open in November, with a deadline for submission announced on 18/02/2016. This program, dedicated to innovative SMEs, aimed at supporting collaborative and European, close to the market R&D projects, (minimum 2 participating European countries). The project funding rate is 30 to 40% of eligible costs.
Contact : Emilie Romeo, European Project Manager – emilie.romeo@lyonbiopole.com


A LA UNE
09/2015 – Health2CARE – 6 new promising projects awarded 

The partners of the European project Health2CARE, including competitiveness clusters Lyonbiopole, Minalogic, Plastipolis, the I-CARE Cluster and the Rhône-Alpes Region announce the support of 6 promising new cross-technology projects around the Personalized Health. Following the 2nd call for expressions of interest launched last May, companies and project developers Fluoptics, Historam, Horuscare, Life Science Development, LX Repair and Rheonova, members of Lyonbiopole, were selected among the 13 projects presented to a jury of European experts. These companies will benefit from support for their projects through a system of "innovation vouchers" of between € 7 000 and € 15 000 to enable for external expertise (business development, search for private financing, access to European markets .. .) to accelerate market entry of their products. Find here the Directory of project holders that participate in the calls.
Contact : Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

09/14/2015 - ERYTECH submits marketing authorization application

This request is addressed to the European Medicines Agency (EMA) about ERY-SPA for the treatment of patients with Acute Lymphoblastic Leukemia (ALL). Erytech also named Eric Soyer as CFO and COO of the company.

Learn more


09/14/2015 - ElsaLys Biotech obtains 1,57 million euros

ElsaLys Biotech announced that the FUI (Fonds Unique Interministry – Single Interministerial Fund) has been granted of a 1.57 million euros subsidy to the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project.

Learn more


09/11/2015 - Biom’Up secures 31,3 million euros

Biom’Up today announced that the company has secured EUR 31,3 million in a Series C financing round from an investment syndicate consisting of Gimv, Bpifrance Large Venture and Lundbeckfond Ventures, alongside its existing shareholders (InnoBio, Sham Innovation Santé, ACG Management, Sofimac, Mérieux Développement, OTC AM, Euroainvest and l’Améliane) and the company’s management team.

Learn more


09/24/2015 - Adocia initiates a clinical study

Adocia announced the initiation of a Phase I clinical trial evaluating a new and more concentrated formulation of BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. This formulation uses Adocia’s proprietary BioChaperone technology, which enables the acceleration of insulin absorption.

Learn more


09/2015 - Bactup enriches its offer

Bactup is a company specializing in microbiological analyzes, identification, production and preservation of microbial strains. Based in Lyon since 2007, its customers are from the pharmaceutical, cosmetics and biotechnology. GMP compliance, the laboratory also carries out method validation or R&D studies for its clients. With its experience, Bactup also offers now, expertise and advice to master microbial contamination or otherwise enhance the strains of interest . A new website to discover!

 


07/30/2015 -  Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, and ImmunID, an immune molecular diagnostics company, announce an agreement to collaborate on a research project aimed at predicting which patients will respond best to SCIB1 treatment. The study will use ImmunID’s flagship clinical product, ImmunTraCkeR®, before and during treatment, to assess the immune-modulatory effect of Scancell’s SCIB1 ImmunoBody® vaccine in patients with Stage III/IV metastatic melanoma.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |